Janssen Pharmaceutica N.V.
Turnhoutseweg 30
Beerse
Antwerpen
2340
Tel: 32-14602226
89 articles with Janssen Pharmaceutica N.V.
-
Essential Pharma Announces the Acquisition of HALDOL®
12/7/2022
Essential Pharma announces that it has completed the acquisition of HALDOL® and HALDOL® Decanoate from Janssen Pharmaceutica NV.
-
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
12/5/2022
Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV.
-
Evotec Enters a Drug Discovery Collaboration with Janssen
6/14/2022
Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
4/19/2022
Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.
-
VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen
4/13/2022
VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen’).
-
Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
4/5/2022
Saladax Biomedical, Inc. is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV.
-
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
-
Midatech Pharma PLC Announces R&D Collaboration with Janssen on Second Molecule
3/9/2022
Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce an extension of its existing R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.
-
Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing
2/17/2022
Remix Therapeutics today announced a strategic collaboration with Janssen Pharmaceutica NV for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
-
The strategic collaboration centers on Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
-
Midatech Pharma PLC Announces Extension of Janssen collaboration re Q-Sphera
1/17/2022
Midatech Pharma PLC is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.
-
TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation
1/6/2022
TRexBio Inc. today announced that it has entered into a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
SRI International Announces Collaboration Agreement with Janssen
1/5/2022
SRI International (SRI) today announced the company has entered into a collaboration agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica
11/8/2021
Alkermes plc announced that it received notices of partial termination in respect of two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology.
-
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
3/29/2021
Up to 400 million doses of the Company's single-shot vaccine candidate will be made available to African Union member states
-
Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery
4/29/2019
Iktos, a company specializing in Artificial Intelligence technologies applied to new drug design, announced the initiation of a collaboration agreement with Janssen Pharmaceutica NV.
-
Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
4/12/2019
Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen).
-
Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
4/12/2019
Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen).
-
Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science
1/10/2019
Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research.
-
Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.